Home LiteratureArticle Details
PMID: 27076625 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Comment

Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?

Clinical cancer research : an official journal of the American Association for Cancer Research ·Vol. 22 ·No. 14 ·2016-00-15 ·Pages 3422-4

Datar I, Schalper KA

Abstract

Epithelial-mesenchymal transition (EMT) is a complex process involved in metastasis. Immune evasion is required for tumor progression and is characterized by an ineffective antitumor immune response and upregulation of immune-suppressive signals. The coexistence of EMT and adaptive immune evasion opens the possibility of a mechanistic link between these processes. Clin Cancer Res; 22(14); 3422-4. ©2016 AACRSee related article by Lou et al., p. 3630.

MeSH Terms
Disease Progression Epithelial-Mesenchymal Transition/immunology,physiology Gene Expression Regulation, Neoplastic/immunology Humans Immune Evasion/immunology Lung/immunology,pathology Lung Neoplasms/immunology,pathology Up-Regulation/immunology
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Datar Ila
Department of Pathology, Yale School of Medicine, New Haven, Connecticut. Translational Immuno-oncology Laboratory, Yale Cancer Center, New Haven, Connecticut.
Schalper Kurt A
Department of Pathology, Yale School of Medicine, New Haven, Connecticut. Translational Immuno-oncology Laboratory, Yale Cancer Center, New Haven, Connecticut. Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut. kurt.schalper@yale.edu.
References (14)
14 references, click to expand
  1. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
    Nature. 2014 Nov 27;515(7528):563-7 PMID: 25428504
  2. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway.
    Lab Invest. 2013 Jul;93(7):844-54 PMID: 23752129
  3. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells.
    Cancer Cell. 2009 Mar 3;15(3):195-206 PMID: 19249678
  4. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
    Nature. 2015 Jul 9;523(7559):231-5 PMID: 25970248
  5. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
    Nature. 2014 Nov 27;515(7528):568-71 PMID: 25428505
  6. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
    Science. 2015 Apr 3;348(6230):124-8 PMID: 25765070
  7. Whom to blame for metastasis, the epithelial-mesenchymal transition or the tumor microenvironment?
    Cancer Lett. 2016 Sep 28;380(1):359-68 PMID: 26791236
  8. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.
    Clin Cancer Res. 2016 Jul 15;22(14):3630-42 PMID: 26851185
  9. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
    Mol Cancer. 2015 Aug 07;14:149 PMID: 26245467
  10. Multilayer control of the EMT master regulators.
    Oncogene. 2014 Apr 3;33(14 ):1755-63 PMID: 23604123
  11. The feedback loop between miR-124 and TGF-β pathway plays a significant role in non-small cell lung cancer metastasis.
    Carcinogenesis. 2016 Mar;37(3):333-43 PMID: 26818357
  12. COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells.
    Oncoimmunology. 2015 Jul 9;4(11):e1044712 PMID: 26451317
  13. Pembrolizumab for the treatment of non-small-cell lung cancer.
    N Engl J Med. 2015 May 21;372(21):2018-28 PMID: 25891174
  14. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.
    Nat Commun. 2014 Oct 28;5:5241 PMID: 25348003
Article Info
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Abbr.
Clin Cancer Res
ISSN
1557-3265
DOI
10.1158/1078-0432.CCR-16-0336
Email
kurt.schalper@yale.edu
Published
2016-00-15
Epub
2016-00-13
Pages
3422-4
Language
English
Region
United States
NLM ID
9502500
PMCID
PMC4947415
Subset
IM
Grants
NCI NIH HHS · P50 CA196530 · United States
NCATS NIH HHS · UL1 TR001863 · United States
Corrections
CommentOn
PMID: 26851185
External Links
PubMed source DOI: 10.1158/1078-0432.CCR-16-0336 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2